ArticleOpen forum infectious diseases2020
Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.BMC public health · 2022Pooled it
- Hepatitis C Virus Care Cascade by Race/Ethnicity in a Statewide Correctional Population, 2019-2023.Journal of racial and ethnic health disparities · 2025Article
- Review
- Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.Infectious diseases and therapy · 2024Article
- Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.The Kaohsiung journal of medical sciences · 2024Review
- The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatients.International journal of hepatology · 2024Article
- Chronic hepatitis C elimination prison initiative: HCV-intensive test and treat, a whole prisoner population HCV test-and-treat program in England.Health science reports · 2023Article
- Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.Life (Basel, Switzerland) · 2023Review
- Article
- Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach.PloS one · 2023Article
- Hepatitis C microelimination among people living with HIV in Taiwan.Emerging microbes & infections · 2022Article
- Article
- Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.Journal of general internal medicine · 2022Review
- Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents.Viruses · 2022Article
- Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).Hepatology international · 2022Article
- Taiwan accelerates its efforts to eliminate hepatitis C.Global health & medicine · 2021Review
- The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.Clinical and molecular hepatology · 2021Article
- Update on the management and treatment of viral hepatitis.World journal of gastroenterology · 2021Review
- Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020.The Kaohsiung journal of medical sciences · 2021Review
- The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncarcerated persons are a special population with higher hepatitis C virus (HCV) prevalence and should be prioritized for microelimination. In this study, we investigate the seroprevalence and evaluate the effectiveness and safety of direct-acting antiviral (DAA) therapy in custodial settings.
methodsIncarcerated persons in Yunlin Prison were recruited to receive anti-HCV antibody screening. Patients with positive HCV ribonucleic acid (RNA) were treated with glecaprevir/pibrentasvir (GLE/PIB) in our special chronic hepatitis C (CHC) clinic in prison. The primary endpoint was sustained virologic response at week 12 off therapy (SVR12).
resultsA total of 1402 incarcerated persons were invited to anti-HCV screening and 824 (58.7%) accepted. The prevalence of anti-HCV positivity was 33.5% (276 of 824), and the viremic rate (detectable HCV RNA) was 69.2% (191 of 276). According to fibrosis index based on 4 factors, patients with F3 stage were 6 (3.1%), but none met the criteria of F4 stage. However, 6 (3.1%) had liver cirrhosis with splenomegaly, confirmed by findings of ultrasonography. The median log
conclusionsDirect-acting antiviral therapy is highly effective and safe for incarcerated patients in Taiwan. Our special prison-based CHC clinic, linking universal screening to medical care, can serve as a model for microelimination of HCV in custodial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.